Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

702P - Bladder preservation in elderly with muscle-invasive bladder cancer (MIBC): An observational study with concurrent chemotherapy and twice daily hypofractionated radiation therapy (HFTD) schedule


16 Sep 2021


ePoster Display


Radiation Oncology

Tumour Site

Urothelial Cancer


Aurélia Alati


Annals of Oncology (2021) 32 (suppl_5): S678-S724. 10.1016/annonc/annonc675


A. Alati1, E. Fabiano1, J.E. Bibault1, P. Giraud1, A. Mejean2, S. Kreps1, M. Housset1, C. Durdux1

Author affiliations

  • 1 Radiotherapy, European Georges Pompidou Hospital - APHP, 75015 - Paris/FR
  • 2 Urology, European Georges Pompidou Hospital - APHP, 75015 - Paris/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 702P


Bladder cancer frequently affects older people. However, their management is not consensual since surgery is not always possible in case of geriatric fragility. Trimodal treatment (TMT) combining trans-urethral resection (TURB) plus radiochemotherapy would be a curative alternative to preserve the native bladder.


All patients from 75 years of age with muscle-invasive bladder cancer bladder (MIBC) stage T2-T3N0M0 treated with TMT by European Georges Pompidou oncologic team were analysed. After TURB, induction radiotherapy delivered 3 Gy per fraction twice daily on days 1-3, 15-17 including the bladder and the pelvis. Patients with biopsy-proven complete response after induction benefited from consolidation and those with persistent tumour underwent salvage cystectomy if possible. Consolidation radiotherapy targeted the bladder only and delivered 2.5 Gy per fraction twice daily on days 29-31, 42-44. Concurrent chemotherapy consisted in 5FU and platinum salts.


Eighty-five pts (median age 80 years), stage T2-T3 were included. The median age adjusted Charlson score (ACCI) was 6 and 30% were undernourished. After induction, the complete response rate was 81%. With a median follow-up of 63 months, overall survival (OS), specific survival (SS), survival with no invasive disease (NIDS) and no metastasis (NMS) at 3 years were 72%, 82.5%, 78.4% and 84.9%, at 5 years were 61%, 77%, 71.6% and 82.9% respectively. Preserved bladder survival (PBS) rate was 70 % at 5 years. An ACCI ≥ 6 (HR 0.3; p=0.044) and undernutrition (HR 1.9; p=0.032) significantly impacted OS. A tumor residue after induction had a pejorative impact on survival: SS (HR 3.6; p=0.008), NIDS (HR 3.6; p= 0.018) and NMS (HR 3.3; p=0.003). Late grade ≥ 3 urinary and gastrointestinal toxicities were 2.6% and 1.3%, respectively.


We report here the largest series of bladder preservation in elderly. Undernutrition, ACCI ≥ 6 and presence of a tumor residue after the induction phase are adverse prognostic factors. TMT with HFTD radiation therapy schedule appears to be effective and well tolerated in selected pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.